New Hepatitis Drug Significantly More Effective - Two studies sponsored by drug company Hoffmann-La Roche Inc., found that with modifications, it's interferon drug, Roferon-A, can be made significantly more effective for treatment of hepatitis C. This variation of Roferon-A, named Pagasys, should improve treatment for the 4 million Americans with hepatitis, many of whom are nurses who became exposed to the virus through needlestick injuries.
Results of Hoffmann-La Roche's studies are available in the 12/07/00 New England Journal of Medicine.
ANA was actively involved in advocating for the Needlestick Safety and Prevention Act which was signed into law this November. The Act is designed to protect health care workers from the 800,000 needlesticks injuries which occur annually and puts workers at risk for blood-borne viruses such as HIV and hepatitis C.
(Source: Compiled from Associated Press and Reuters wire reports.)